# Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

> **NCT07715565** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Renal Cell Carcinoma (Kidney Cancer)
- Immunotherapy
- Molecular Targeted Therapy

## Interventions

- **DRUG:** Ipilimumab Injection
- **DRUG:** Sintilimab injection
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07715565
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715565, "Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*